Research Article
Study on the Evaluation of Lung Cancer Patients from the Three Aspects of Emotion
Table 5
Comparison of the QoL between those who have not progressed and those who have progressed after chemotherapy.
| QoL dimension | Pre-chemotherapy score (n = 219) | Post-chemotherapy (disease has not progressed) (n = 175) | T1 value | Post-chemotherapy (disease progression) (n = 44) | T2 value |
| Functional dimension | 68.44 ± 16.28 | 63.52 ± 19.43 | 2.61 | 47.36 ± 23.09 | 4.52 | Overall QoL | 56.28 ± 21.32 | 54.49 ± 19.06 | 0.827 | 40.06 ± 20.66 | 4.30 | Symptom dimension | 27.73 ± 15.26 | 33.72 ± 17.94 | −3.83 | 44.34 ± 18.28 | −3.50 | Lung cancer symptoms | 22.31 ± 13.86 | 22.23 ± 9.37 | 0.05 | 30.95 ± 18.47 | −2.83 | Related side effects | 9.44 ± 8.05 | 19.52 ± 13.15 | −6.69 | 31.18 ± 22.43 | −3.46 |
|
|